Carfilzomib: all 165 studies that test it

Page 1 of 2. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.

• Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingNCT07715903Phase 1
• KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS SyndromeRecruitingNCT07652879Phase 2
• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT07479979Phase 1/2
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingNCT07222761Phase 3
• Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingNCT06918990Phase 1
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNCT06793475Not applicable
• Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingNCT06627751Phase 2
• SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06622005Phase 1
• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06249282Phase 1
• Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Phase 2
• Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT05896228Phase 2
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
• A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingNCT03909412Phase 1
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationNCT03815279Phase 2
• Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT04756401Phase 2Results posted
• KRDI in Transplant-Eligible MMActive, not recruitingNCT04430894Phase 2Results posted
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersTerminatedNCT03512353Phase 2Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaTerminatedNCT03269552Phase 2Results posted
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03256045Phase 2Results posted
• Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
• Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Phase 3Results posted
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• High Dose Carfilzomib for Newly Diagnosed MyelomaCompletedNCT02937571Phase 1/2Results posted
• Carfilzomib and TGR-1202 in Treatment of R/R LymphomaTerminatedNCT02867618Phase 1/2Results posted
• High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple MyelomaCompletedNCT02597062Phase 2Results posted
• A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisCompletedNCT02545907Phase 1/2Results posted
• Carfilzomib in Treating Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT02491359Phase 2Results posted
• Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung TransplantationCompletedNCT02474927Phase 2Results posted
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaCompletedNCT02412878Phase 3Results posted
• Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine CancersCompletedNCT02318784Phase 2Results posted
• Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple MyelomaCompletedNCT02148913Phase 1Results posted
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic MalignanciesCompletedNCT02145403Phase 1/2Results posted
• Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaCompletedNCT02073097Phase 1/2Results posted
• Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following TreatmentCompletedNCT02047253Phase 2Results posted
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT02042950Phase 2Results posted
• Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line TherapyTerminatedNCT02020941Phase 2Results posted
• Carfilzomib With Bendamustine and Dexamethasone in Multiple MyelomaTerminatedNCT02002598Phase 1/2Results posted
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung CancerCompletedNCT01987232Phase 1/2Results posted
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01980589Phase 1Results posted
• Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple MyelomaTerminatedNCT01969565Phase 2Results posted
• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaActive, not recruitingNCT01959698Phase 1Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic ImpairmentCompletedNCT01949545Phase 1Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal DiseaseCompletedNCT01949532Phase 1Results posted
• Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer PatientsCompletedNCT01941316Phase 1/2Results posted
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaCompletedNCT01903811Phase 2Results posted
• Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01842308Phase 1/2Results posted
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Phase 3Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted
• A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531CompletedNCT01813227Phase 2Results posted
• Carfilzomib in Refractory Renal Cell Carcinoma (RCC)CompletedNCT01775930Phase 2Results posted
• Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose CarfilzomibCompletedNCT01775553Phase 2Results posted
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationCompletedNCT01690143Phase 1/2Results posted
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaCompletedNCT01677858Phase 1/2Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple MyelomaCompletedNCT01572480Phase 2Results posted
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsCompletedNCT01568866Phase 3Results posted
• Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple MyelomaCompletedNCT01559935Phase 2Results posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaCompletedNCT01470196Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01351623Phase 2Results posted
• A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01302392Phase 3Results posted
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaCompletedNCT01080391Phase 3Results posted
• Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaCompletedNCT01057225Phase 1/2Results posted
• Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple MyelomaCompletedNCT01029054Phase 1/2Results posted
• A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment ProtocolsCompletedNCT00884312Phase 2Results posted
• Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal FunctionCompletedNCT00721734Phase 2Results posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Phase 2 Study of Carfilzomib in Relapsed Multiple MyelomaCompletedNCT00530816Phase 2Results posted
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaCompletedNCT00511238Phase 2Results posted
• A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT06356571Phase 2
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05704049Phase 2
• A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05675449Phase 1
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaSuspendedNCT05199311Phase 1/2
• Carfilzomib and Belatacept for DesensitizationActive, not recruitingNCT05017545Phase 1/2
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialActive, not recruitingNCT04764942Phase 1/2
• Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
• A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaActive, not recruitingNCT04268498Phase 2
• Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's MacroglobulinemiaActive, not recruitingNCT04263480Phase 2

← Carfilzomib overview